Literature DB >> 31045631

How to best measure quality of life in coeliac disease? A validation and comparison of disease-specific and generic quality of life measures.

Jordy P W Burger1, H van Middendorp2, Joost P H Drenth3, Peter J Wahab1, Andrea W M Evers2.   

Abstract

OBJECTIVE: Health-related quality of life (HRQoL) is an important outcome in chronic disease. Generic HRQoL questionnaires may not adequately reflect disease-specific challenges in coeliac disease. We investigated whether disease-specific HRQoL questionnaires add relevant information to generic measures that will better help to identify patients experiencing problems. PATIENTS AND METHODS: We performed a cross-cultural validation of the Celiac Disease Quality Of Life-survey (CD-QOL), next we developed and validated a new disease-specific HRQoL questionnaire, and finally compared their predictive validity with the disease-generic RAND SF-36/SF-12 in 825 patients (mean age: 56.1±15.8 years) with (reported) biopsy-proven coeliac disease. Internal consistency and convergent, discriminative and predictive validity of the questionnaires was determined.
RESULTS: Two Dutch versions of the CD-QOL were validated, consisting of 14 and six items, respectively (CD-QOL-14-NL, CD-QOL-6-NL). We developed and validated the CeliacQ-27, which has 27-items across three subscales (Limitations, Worries and Impact on daily life), and a short seven-item version, the CeliacQ-7. All questionnaires had excellent psychometric properties and differentiated well between active disease and clinical remission and strict versus poor dietary adherence. The added value of the disease-specific questionnaires to the generic HRQoL measure to the explained variance of symptom burden and dietary adherence was limited.
CONCLUSION: HRQoL in patients with coeliac disease can easily be assessed by brief generic as well as disease-specific measures. Disease-specific questionnaires, however, provide more explicit information on disease-relevant areas of functioning.

Entities:  

Year:  2019        PMID: 31045631     DOI: 10.1097/MEG.0000000000001432

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  2 in total

1.  Dose-Escalating (50-500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial.

Authors:  Jordy P W Burger; Ellen G van Lochem; Elisabeth A Roovers; Joost P H Drenth; Peter J Wahab
Journal:  Nutrients       Date:  2022-04-23       Impact factor: 6.706

2.  The Persian Translation and validation of the celiac disease quality of life questionnaire (CDQOL).

Authors:  Zeinab Nikniaz; Mohammad Asghari Jafarabadi; Saeedeh Ghaffarifar; Zahra Ravand; Zahra Akbari Namvar; Masood Shirmohammadi
Journal:  Health Qual Life Outcomes       Date:  2021-02-10       Impact factor: 3.186

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.